Latest 4 stories · newest Nov 5, 2026
Shattuck Labs initiated a Phase 2 clinical trial for its lead DR3 antibody candidate SL-325 in hidradenitis suppurativa. This diversifies its clinical pipeline and positions the company for future growth in the inflammatory disease therapeutics market.
Shattuck Labs is conducting an underwritten public offering of 10.9 million common shares and 7.9 million pre-funded warrants with representatives including Leerink Partners, J.P. Morgan Securities, Piper Sandler, and Cantor Fitzgerald. The offering is expected to raise capital for the biotech compa…
Shattuck Labs reported Phase 1 data for SL-325 showing a potentially best-in-mechanism immunogenicity profile with only 3.7% antidrug antibodies and complete TL1A blockade lasting over 3 months. The company plans to initiate Phase 2b trials in Crohn's disease in Q3 2026, advancing its pipeline of DR…
Shattuck Labs adopted an amended and restated 2020 Equity Incentive Plan, succeeding the prior 2016 plan with enhanced award provisions for employees, directors and consultants. The update reflects standard corporate governance practices to maintain competitive compensation structures for talent ret…
The same STTK feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/STTK/newsSTART FREE